Navigation Links
Pacira Pharmaceuticals, Inc. Reports Second Quarter 2011 Financial Results
Date:8/11/2011

-looking statements include, among others, statements about: the company's plans to develop and commercialize EXPAREL; the Company's plans to continue to manufacture and provide support services for its commercial partners who have licensed DepoCyt(e) and DepoDur; the timing of, and the Company's ability to obtain, regulatory approval of EXPAREL; the timing of the Company's anticipated commercial launch of EXPAREL; the rate and degree of market acceptance of EXPAREL; the size and growth of the potential markets for EXPAREL and the Company's ability to serve those markets; the Company's plans to expand the indications of EXPAREL to include nerve block and epidural administration; and our commercialization and marketing capabilities.  Important factors could cause our actual results to differ materially from those indicated or implied by forward-looking statements; including, the Company is dependent on the success of EXPAREL and cannot guarantee that it will receive regulatory approval or be successfully commercialized; the Company faces significant competition and its operating results will suffer if it fails to compete effectively; if the Company is unable to establish effective marketing and sales capabilities or enter into agreements with third parties to handle marketing and sales, the Company may be unable to generate product revenues; if EXPAREL does not achieve broad market acceptance, the revenues that Company generates from its sales will be limited; the Company may not receive regulatory approval for EXPAREL or the approval may be delayed; the Company has incurred significant losses since its inception and anticipates that it will incur continued losses for the foreseeable future; the Company will need to raise additional financing to continue as a going concern and may be unable to raise capital when needed; and those risks discussed in "Risk Factors" and elsewhere in Pacira Pharmaceuticals'  Annual Report on Form 10-K,  filed with the Secu
'/>"/>
SOURCE Pacira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Pacira Pharmaceuticals, Inc. Announces Data Presentations at the 38th Annual Meeting & Exposition of the Controlled Release Society
2. Pacira Pharmaceuticals, Inc. Announces Timing for Second Quarter 2011 Financial Results Webcast and Conference Call
3. Pacira Pharmaceuticals, Inc. Announces Inclusion in Russell 3000 Index
4. Pacira Pharmaceuticals, Inc. Announces FDA Extension of EXPAREL™ PDUFA Target Date by Three Months
5. Pacira Pharmaceuticals, Inc. Appoints Two Life Sciences Industry Veterans to Its Board of Directors
6. Pacira Pharmaceuticals, Inc. to Present at UBS Global Specialty Pharmaceuticals Conference
7. Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data Presentations at the International Anesthesia Research Society 2011 Annual Meeting
8. Pacira Pharmaceuticals, Inc. Announces Phase 3 EXPAREL™ Data Presentation at the American Society of Colon and Rectal Surgeons 2011 Annual Meeting
9. Pacira Pharmaceuticals, Inc. Reports First Quarter 2011 Financial Results
10. Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data Presentations
11. Pacira Pharmaceuticals, Inc. Announces Timing for First Quarter 2011 Financial Results Webcast and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... , Oct. 31, 2014  Lycera Corp., a ... treat autoimmune disease and cancer, today announced that ... RORgamma agonist product candidates will be presented at ... of Cancer (SITC) being held November 6-9, 2014 ... National Harbor, MD.  The poster, entitled " Novel ...
(Date:10/31/2014)... California , November 3, 2014 ... need for men with BPH to discuss "male orgasmic ... system shows ability to treat prostate symptoms while preserving ... Inc., today welcomes the publication of a paper in ... men suffering from enlarged prostate to discuss with their ...
(Date:10/31/2014)... , October 30, 2014 ... has announced the addition of the  "Process Validation ... to their offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... Science and Risk Based Approach to Process Validation ... Risk Management FDA Process Validation Guidance ...
Breaking Medicine Technology:Lycera Announces Presentation of Data on Anti-Tumor Activity of Novel Synthetic RORgamma Agonists at Society for Immunotherapy of Cancer Meeting 2Sexual Dysfunction No Longer Inevitable When Treating Enlarged Prostate 2Process Validation in the US and EU (Workshop, London) 2Process Validation in the US and EU (Workshop, London) 3Process Validation in the US and EU (Workshop, London) 4
... Investment in Vaccine to Prevent Rotavirus, NEW ... that it has purchased a royalty interest in ... an oral,vaccine developed to prevent rotavirus infection, a ... infants and young children.,The product is marketed by ...
... The Public Patent,Foundation ("PUBPAT") announced today that the U.S. ... patents held by Gilead Sciences,that relate to the drug ... in the battle against HIV/AIDS. Gilead markets TDF in,the ... a part of its ATRIPLA,combination product., Roughly 40 ...
Cached Medicine Technology:Paul Capital Healthcare Purchases Additional Royalty Interest in GlaxoSmithKline's Rotarix(R) 2U.S. Patent Office Rejects Key HIV/AIDS Drug Patents at PUBPAT Request: Government Finds Prior Art Submitted By PUBPAT Invalidates All of Gilead Sciences' Claims 2
(Date:10/31/2014)... central to life. The last stage, when two daughter ... the dawn of cell biology in the Victorian era. ... to study this final step, when the dividing cell ... name given to this process by those early biologists, ... of a highly active and organized series of events. ...
(Date:10/31/2014)... its kind, Rice University researchers have mapped how information ... to become metastatic. The research reveals a common pattern ... migrate and form new tumors. Researchers say the commonality ... with the genetic switches that cancer must flip to ... -- two of the main players in cancer metastasis. ...
(Date:10/31/2014)... Friday. October 31, 2014 — A team from ... and the University of California, Santa Cruz, was ... Cancer Genomics Cloud Pilot contracts with the goal ... analysis of The Cancer Genome Atlas (TCGA) and ... required computing resources in one cloud environment. This ...
(Date:10/31/2014)... Daily Gossip writes in its Xtreme Fat Loss ... fastest fat loss program ever developed. It promises to provide ... There is no wonder after all that this has become ... new nutrition and workout fat loss program was created by ... According to the author of this fat loss system, the ...
(Date:10/31/2014)... (PRWEB) October 31, 2014 This ... has amazing health effects for practitioners. , ... a Doctor of Science and Movement specializing in ... dedication to pelvic floor reeducation that traditional abdominal ... incontinence, Diastasis Recti, Prolepses, etc. , The Hipopressives ...
Breaking Medicine News(10 mins):Health News:Cell division, minus the cells 2Health News:Cell division, minus the cells 3Health News:Decoding the emergence of metastatic cancer stem cells 2Health News:Decoding the emergence of metastatic cancer stem cells 3Health News:Broad Institute, Univ. of California team awarded NCI Cancer Genomics Cloud Pilot contract 2Health News:Broad Institute, Univ. of California team awarded NCI Cancer Genomics Cloud Pilot contract 3Health News:Xtreme Fat Loss Diet Review Reveals How to Transform Your Body in 25 Days 2Health News:Super Models and European Celebrities’ Secret Flat Tummy System Comes to America 2Health News:Super Models and European Celebrities’ Secret Flat Tummy System Comes to America 3
... A research from Australian company has finalized development ... take the guesswork out of diagnosing melanomas, the ... managing director of Polartechnics said that in terms ... top specialists.// ,Image analysis and computer-aided diagnostic ...
... radiation alone may be enough to treat some patients ... France studied 60 patients between 1985 and 1999.// Typical ... patients surgery is not an option. ,In this ... eligible for surgery to remove it. A combination radiation ...
... that red wine drinkers have increased HDL cholesterol, commonly ... some light on why red wine is believed to ... HDL cholesterol levels between 40 men who drink every ... those who are heavy drinkers. As alcohol consumption shot ...
... no longer the dirty word for consumers that it was ... in eating lower fat foods. There are more than ... being fat-free or low-fat milk// products and salad dressings. ... made from starch, protein, or fat. ,Most fat substitutes ...
... the University of Michigan, made a new study ... after head and neck surgery. Ann Arbor say leeches are ... have surgery// to remove cancer in and around the head ... ,Doctors say about 15 percent of patients develop obstructions that ...
... into energy-producing muscle fibres – mocking the effect of ... protein in muscle called PGC-10.// Now, with colleagues at ... has the power to transform muscle fibres. ... is the easily-fatigued type, which is predominant among those ...
Cached Medicine News:Health News:Latest device for identifying Melanomas 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: